Phe-met-arg-phe-amide (FMRF-NH2) inhibits insulin and somatostatin secretion and anti-FMRF-NH2 sera detects pancreatic polypeptide cells in the rat islet.
FMRF-NH2-like immunoreactivity was localized in the pancreatic polypeptide containing cells of the rat islet. FMRF-NH2 was investigated with regard to its effect on insulin, somatostatin and glucagon secretion from the isolated perfused rat pancreas. FMRF-NH2 (1 microM) significantly inhibited glucose stimulated (300 mg/dl) insulin release (p less than 0.005) and somatostatin release (p less than 0.01) from the isolated perfused pancreas. FMRF-NH2 (1 and 10 microM) was without effect on glucagon secretion, either in low glucose (50 mg/dl), high glucose (300 mg/dl), or during arginine stimulation (5 mM). These findings indicate that these FMRF-NH2 antisera recognize a substance in the pancreatic polypeptide cells of the islet which may be capable of modulating islet beta and D cell activity.
D000818:Animals; D000936:Antigen-Antibody Complex; D001120:Arginine / Q000494:pharmacology; D019835:FMRFamide; D005455:Fluorescent Antibody Technique; D005934:Glucagon / Q000378:metabolism; D005947:Glucose / Q000494:pharmacology; D007106:Immune Sera; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009842:Oligopeptides / Q000276:immunology / Q000494:pharmacology*; D010191:Pancreatic Polypeptide / Q000032:analysis*; D010477:Perfusion; D051381:Rats; D013004:Somatostatin / Q000378:metabolism*
D000936:Antigen-Antibody Complex; D007106:Immune Sera; D007328:Insulin; D009842:Oligopeptides; D013004:Somatostatin; D010191:Pancreatic Polypeptide; D019835:FMRFamide; D005934:Glucagon; D001120:Arginine; D005947:Glucose